Affimed NV (Affimed NV) Pre-Tax Income

: $-114.11 Mil (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

Pretax income is the income that a company earns before paying income taxes. Affimed NV's pretax income for the three months ended in Dec. 2023 was $-22.03 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-114.11 Mil. Affimed NV's pretax margin was -4,896.44%.

During the past 12 years, Affimed NV's highest Pretax Margin was -12.57%. The lowest was -1504.46%. And the median was -179.63%.

Affimed NV Pre-Tax Income Historical Data

The historical data trend for Affimed NV's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

-35.96

-50.32

-65.00

-91.10

-115.52

Affimed NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Pre-Tax Income																-35.42	-34.24	-31.85	-25.99	-22.03

Competitive Comparison

For the Biotechnology subindustry, Affimed NV's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Affimed NV Pre-Tax Income Distribution

For the Biotechnology industry and Healthcare sector, Affimed NV's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Affimed NV's Pre-Tax Income falls into.

Affimed NV Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Affimed NV's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-121.197	+	5.414	+	-1.969	+	0.555	+	1.674
	=	-115.52

Affimed NV's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-26.381	+	4.277	+	-0.449	+	0.405	+	0.114
	=	-22.03

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-114.11 Mil.

Affimed NV (NAS:AFMD) Pre-Tax Income Explanation

Affimed NV's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-22.034	/	0.45
	=	-4,896.44%

During the past 12 years, Affimed NV's highest Pretax Margin was -12.57%. The lowest was -1504.46%. And the median was -179.63%.

Affimed NV Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Affimed NV's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Affimed NV (Affimed NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (NAS:AFMD) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

A28:Germany

Address

Im Neuenheimer Feld 582, Technologiepark, Heidelberg, BW, DEU, 69120

Website

https://www.affimed.com

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.